Dermatology Practice Near Boston First in the World to Offer Novel Cellulite Treatment Cellfina™
Chestnut Hill, Massachusetts (PRWEB) April 09, 2015 -- SkinCare Physicians is delighted to have been the first dermatology practice in the world to offer Cellfina, the only FDA-cleared minimally invasive procedure, clinically proven to improve the appearance of cellulite for at least one year - the longest FDA clearance for a cellulite treatment. Our practice has also helped train the twelve other cosmetic centers in the United States, as nearly all of the scientific work, protocol development and clinical research that led to Cellfina’s FDA clearance was performed at SkinCare Physicians over the last several years.
“We are extremely pleased to bring this unique procedure to our patients,” says Michael Kaminer M.D., a founding partner of SkinCare Physicians. “We now know that cellulite is caused by fibrous cords under the skin that pull down and cause the disturbing dimples. Cellfina uses an innovative technology that enables us to safely and precisely release the fibrous bands under the dimpled areas with a small releasing tool.”
Cellfina reduces the appearance of cellulite in just one treatment session, and works best on the outer thighs and the buttocks.
“Our patients want effective treatments with minimal discomfort and limited downtime so they can return to their daily activities soon after the procedure," shares SkinCare Physicians’ Dr. Deanne Robinson, one of the scientific investigators along with lead investigator Dr. Kaminer. "With Cellfina, patients get the convenience of a minimally-invasive procedure that works and takes approximately an hour depending on the patients and the number of areas treated."
Within just three days after treatment, patients in the FDA-cleared pivotal study reported feeling very satisfied with their results. At three months, 85% of patients were satisfied, and after one year, 94% were satisfied, surpassing patient satisfaction rates for all other cellulite treatments. There were zero long term complications, and recovery was complete within 48-72 hours.
“Because of our long standing interest in cellulite and our research capabilities, SkinCare Physicians was chosen as the main investigative site for the initial pivotal study,” Dr. Kaminer continues. “However, while Cellfina has been cleared by the FDA, clinical research is not over.” SkinCare Physicians will now be the lead site in what is known as the CRUISE registry study, which will evaluate over 100 treatments performed across 13 sites in the United States. “We are very proud to have been selected as the lead center for the other 12 sites,” Dr. Kaminer adds.
If you're looking for long-lasting cellulite improvements, SkinCare Physicians can help. Call 617-731-1600 to schedule a consultation with Dr. Michael Kaminer who is performing all of the initial treatments.
SkinCare Physicians is a comprehensive, state-of-the-art center for cosmetic and laser surgery, dermatology, dermatologic and skin cancer surgery, and medical aesthetics. The doctors at SkinCare Physicians are internationally renowned innovators and leaders in all of these fields, and the academic accomplishments of this group of physicians is respected throughout the world. They are authors or co-authors of more than 1000 articles in scientific publications, authors or editors of more than 250 books and book chapters, and serve as editors or on editorial boards of more than a dozen journals. Our physicians have been elected or appointed to senior leadership positions in dermatology, cosmetic surgery, laser, and surgery organizations, and have been awarded honorary memberships in many national and international medical and scientific societies.
Our commitment to excellence, along with the credentials of our skilled physicians and staff, are what make SkinCare Physicians one of the most unique and progressive facilities of its kind in the world.
Christine Foley, SkinCare Physicians, http://www.skincarephysicians.net, +1 617-731-1600 Ext: 1704, [email protected]
Share this article